Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trail of the German CLL Study Group (GCLLSG).

被引：6
|
作者：
Fischer, Kirsien [1 ]
Stilgenbauer, Stephan [2 ]
Schweighofer, Carmen D. [1 ]
Renschler, Jasmin [1 ]
Busch, Raymonde [3 ]
Kiehl, Michael [4 ]
Balleisen, Leopold [5 ]
Eckart, Michael [6 ]
Fink, Anna M. [1 ]
Boettcher, Sebastian [7 ]
Ritgen, Matthias [7 ]
Kneba, Michael [7 ]
Staib, Peter [1 ]
Doehner, Hartmut [2 ]
Eichhorst, Barbara F. [1 ]
Hallek, Michael [1 ]
机构：
[1] Univ Hosp, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp, Dept Internal Med, Ulm, Germany
[3] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany
[4] Hospital, Dept Internal Med, Frankfurt, Germany
[5] Hospital, Dept Internal Med, Hamm, Germany
[6] ISP Naegelsbacherstr, Erlangen, Germany
[7] Univ Hosp, Dept Internal Med, Kiel, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.3106.3106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3106
引用
收藏
页码：913A / 914A
页数：2
相关论文
共 50 条
  • [41] A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    LEUKEMIA & LYMPHOMA, 2004, 45 (11) : 2269 - 2273
  • [42] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Badoux, Xavier C.
    Keating, Michael J.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Sargent, Rachel L.
    Kantarjian, Hagop M.
    Ferrajoli, Alessandra
    BLOOD, 2011, 118 (21) : 448 - 448
  • [43] RITUXIMAB PLUS BENDAMUSTINE IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Lucania, A.
    Villa, M. R.
    Izzo, G. Nitrato
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [44] Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    Eichhorst, Barbara F.
    Bahlo, Jasmin
    Maurer, Christian
    Lange, Elisabeth
    Koppler, Hubert
    Kiehl, Michael G.
    Sokler, Martin
    Schlag, Rudolf
    Vehling-Kaiser, Ursula
    Kochling, Georg
    Ploger, Christoph
    Gregor, Michael
    Plesner, Torben
    Herling, Marco
    Fischer, Kirsten
    Dohner, Hartmut
    Kneba, Michael
    Wendtner, Clemens
    Klapper, Wolfram
    Kreuzer, Karl-Anton
    Bottcher, Sebastian
    Stilgenbauer, Stephan
    Fink, Anna Maria
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [45] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Badoux, Xavier
    Estrov, Zeev
    Schlette, Ellen
    Smith, Susan C.
    Ayala, Ana B.
    Falchi, Lorenzo
    Calin, Steliana
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2011, 118 (21) : 780 - 780
  • [46] Final follow-up of a Phase I dose-ranging study of Bendamustine and Rituximab (BR) in patients with chronic lymphocytic leukemia (CLL) with comorbidities
    Danilov, Alexey
    Lewis, Lionel
    Brown, Jennifer
    LEUKEMIA & LYMPHOMA, 2017, 58 : 10 - 10
  • [47] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [48] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [49] EFFICACY OF THE COMBINATION OF BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Ovsepyan, V.
    Shardakov, V.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [50] A phase I/II study of the SYK inhibitor entospletinib in combination with obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Kittai, Adam
    Hashiguchi, Taylor
    Thurlow, Bria
    Gokcora, Basak
    Stadnik, Andrzej
    MacKinnon, Renee
    Stephen, Monette
    Moore, Lacey
    Persky, Daniel
    Park, Byung
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2020, 61 : 76 - 77
12345